Akari Therapeutics
AKTX | NASDAQ
$8.36
+$0.12 (+1.46%)
Nov 2, 2026, 9:39 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Net Income | -17.3M | -19.79M | -10.01M | -17.75M | -17.42M | -17.08M |
Depreciation & Amortization | n/a | 14K | 4K | 4K | 4.13K | 8.91K |
Stock-Based Compensation | 2.89M | 2.25M | 1.15M | 735K | 314.65K | 325.52K |
Other Working Capital | -404K | 6.54M | -866K | 822K | -1.74M | -55.63K |
Other Non-Cash Items | 5.33M | -1.56M | -6.71M | -5.32M | 242.5K | -147.59K |
Deferred Income Tax | -1.09M | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -404K | 6.54M | -866K | 822K | -1.98M | -55.63K |
Operating Cash Flow | -10.57M | -12.55M | -16.43M | -21.5M | -18.85M | -16.95M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | 382K | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | 382K | n/a | n/a | n/a | n/a |
Debt Repayment | 1.05M | -855K | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 28K | 4K | 94K | n/a | 27.5K |
Financial Cash Flow | 13.17M | 10.99M | 7.02M | 25.29M | 14.29M | 25.07M |
Net Cash Flow | 2.6M | -1.19M | -9.41M | 3.89M | -4.69M | 8.32M |
Free Cash Flow | -10.57M | -12.55M | -16.43M | -21.5M | -18.85M | -16.95M |
Adj. Free Cash Flow | -13.46M | -14.8M | -17.58M | -22.24M | -19.16M | -17.28M |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -10.57M | -12.55M | -16.43M | -21.5M | -18.85M | -16.95M |
Add to Watchlist
Select watchlists to add or remove AKTX